OnCo
termsTerm

FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX

aka FOLFOX, mFOLFOX6, FOLFIRI, FOLFOXIRI, FOLFIRINOX, mFOLFIRINOX, modified FOLFIRINOX, CAPOX, XELOX, CAPEOX, NALIRIFOX, FOLFOX/CAPOX, fluoropyrimidine-based

The standard chemotherapy recipes for bowel and pancreatic cancer, named from their ingredients: FOL (folinic acid) + F (5-fluorouracil) + OX (oxaliplatin), IRI (irinotecan), or both (FOLFIRINOX). CAPOX swaps the 5-FU infusion for capecitabine tablets.

FOLFOX or CAPOX for 3-6 months is adjuvant therapy for stage III colon cancer (IDEA showed 3 months suffices for low-risk disease); FOLFOX or FOLFIRI with an antibody (bevacizumab, or cetuximab/panitumumab for left-sided RAS wild-type) is first-line metastatic treatment, with FOLFOXIRI for fit patients needing maximal response. FOLFIRINOX (2011) and NALIRIFOX are the most active pancreatic regimens for fit patients, and FOLFOX is part of total neoadjuvant therapy for rectal cancer and of gastric and biliary regimens. Oxaliplatin causes cumulative cold-triggered neuropathy, irinotecan causes diarrhoea and neutropenia (UGT1A1-dependent).

Category
Treatment jargon

Connected

13top

Pages like this

not linked directly; found by shared links